Forest Laboratories, Inc. Forest Laboratories Holdings, Ltd., Merz Pharma GmbH & Co. KGaA, and Merz Pharmaceuticals GmbH announced today that they have entered into settlement agreements with all remaining defendants in patent infringement litigation related to Forest’s NAMENDA® (memantine hydrochloride) immediate release tablets. Continue Reading
The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month’s issue of Journal of Neurology. This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease. Continue Reading
Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Sandoz, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets. Continue Reading
New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment. Continue Reading
DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application. Continue Reading
A University of Michigan study recently published in Academic Emergency Medicine says that it is common for patients 65 and older to receive potentially inappropriate medications when treated in an emergency room. Continue Reading
Implantable Provider Group, a leading provider of implantable device management, announced today that it has secured an investment from Sequoia Capital. The funding will enable IPG to invest in future growth initiatives. Continue Reading
Mayo Clinic has been designated a comprehensive epilepsy treatment center by the National Association of Epilepsy Centers (NAEC). Only the top epilepsy programs – those that can provide the most complex and advanced care – are selected for this designation, according to the association. Continue Reading
New research shows women who don’t receive a clot-busting drug after a stroke fare worse than men who are not treated. The study is published in the March 2, 2010, print issue of Neurology®, the medical journal of the American Academy of Neurology. Continue Reading
The recovery of consciousness following traumatic brain injury and recent advances in neuroimaging and deep brain stimulation will be discussed at the 14th Annual Swartz Foundation Mind/Brain Lecture at Stony Brook University on Monday, March 15, 2010 at 4:30 p.m. in the Staller Center for the Arts. Continue Reading
